Category: Australia & Regulation
TGA decisions, scheduling, advertising rules, safety communications and Australian therapeutic-goods policy.
TGA Peptide Enforcement 2026: What the Retatrutide, CJC-1295 and Wolverine Stack Case Shows
The TGA's August 2026 enforcement action illustrates how importing, relabelling and social-media advertising create separate legal and safety risks around unapproved peptides.
Read analysis →BPC-157 Australia (2026): TGA Scheduling, Human Evidence, FDA Safety and WADA Status
A source-led guide to BPC-157 in Australia: what Schedule 4 means, what human evidence exists, why online healing claims run ahead of the data, and how…
Read analysis →GLP-3 Australia: What the Term Means, Retatrutide Evidence and TGA Status
What “GLP-3 Australia” usually means, why the term is informal, how it maps to retatrutide’s three receptor targets, and the current TGA position.
Read analysis →ARTG, Unapproved Therapeutic Goods and Clinical Trials: An Australian Reader’s Guide
How to distinguish ARTG inclusion, clinical-trial access, exemptions, overseas approval and online ‘research use only’ claims in Australia.
Read analysis →TGA Retatrutide Alert: Semaglutide Found in Tested Vial
The TGA says a product sold as retatrutide contained undeclared semaglutide, no retatrutide, and was linked to a serious adverse event. What the 14 September 2026…
Read analysis →Retatrutide Trial Tracker: Phase 2 Evidence, Phase 3 Results and Regulatory Status
Updated 6 October 2026: peer-reviewed TRIUMPH-1 Phase 3 results, estimand differences, the wider trial programme, safety findings and current Australian regulatory status.
Read analysis →